Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 83
- Registration Number
- NCT00652327
Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED)
Phase 4
Completed
- Conditions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 80
- Registration Number
- NCT00651963
Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 87
- Registration Number
- NCT00651378
Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 82
- Registration Number
- NCT00651014
Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 122
- Registration Number
- NCT00650689
Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 144
- Registration Number
- NCT00651274
Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 240
- Registration Number
- NCT00650819
Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 28
- Registration Number
- NCT00651391
Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 40
- Registration Number
- NCT00651144
Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 247
- Registration Number
- NCT00650663
© Copyright 2024. All Rights Reserved by MedPath